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Loss of hypocretin (orexin) neurons with traumatic brain injury
Abstract
Chronic, daytime sleepiness is a major, disabling symptom for many patients with traumatic brain injury
(TBI), but thus far, its etiology is not well understood. Extensive loss of the hypothalamic neurons that
produce the wake-promoting neuropeptide hypocretin (orexin) causes the severe sleepiness of
narcolepsy, and partial loss of these cells may contribute to the sleepiness of Parkinson disease and other
disorders. We have found that the number of hypocretin neurons is significantly reduced in patients with
severe TBI. This observation highlights the often overlooked hypothalamic injury in TBI and provides
new insights into the causes of chronic sleepiness in patients with TBI.
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Abstract 
 
Chronic, daytime sleepiness is a major, disabling symptom for many patients with 
traumatic brain injury (TBI), but thus far, its etiology is not well understood. Extensive loss of 
the hypothalamic neurons that produce the wake-promoting neuropeptide hypocretin (orexin) 
causes the severe sleepiness of narcolepsy, and partial loss of these cells may contribute to 
the sleepiness of Parkinson’s disease and other disorders. We have found that the number of 
hypocretin neurons is significantly reduced in patients with severe TBI. This observation 
highlights the often overlooked hypothalamic injury in TBI and provides new insights into the 
causes of chronic sleepiness in patients with TBI. 
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Introduction 
Approximately 1.4 million people sustain traumatic brain injury (TBI) each year In the 
United States.1 Coma and obtundation are common during the acute period, but even after 6 
months recovery, 43% of patients have symptoms of sleep disorders.2,3 In a prospective study 
of 65 TBI patients, 1 in 4 patients reported excessive daytime sleepiness (EDS) irrespective of 
the location or severity of the head trauma.2 Another study of 87 patients revealed similar 
results, with sleepiness in 25% after TBI.3
Though chronic sleepiness is common after head trauma, the cause remains 
unclear. Injury to ascending arousal pathways from the brainstem may contribute, but recent 
findings suggest a key role for the neuropeptides hypocretin-1 and -2 (also known as orexin-A 
and -B).2,4,5 Hypocretins are made by a small cluster of neurons in the lateral hypothalamus 
that play an essential role in promoting wakefulness. Selective loss of the hypocretin-producing 
neurons causes sleepiness and cataplexy in over 90% of patients with narcolepsy,5-9 and 
identical symptoms occur in mice genetically lacking hypocretins.10 Injury to the hypothalamus 
is common in patients with TBI,11 but its clinical impact remains unclear. We recently found that 
TBI patients have a marked reduction in CSF hypocretin-1 levels in the first days after injury.4 
Even after 6 months recovery, many TBI patients with EDS have persistently low hypocretin-1 
levels.2 Thus, we hypothesized that posttraumatic sleepiness is caused, at least in part, by 
injury to the wake-promoting hypocretin neurons.  
 
Methods 
Subjects. We collected brains at autopsy from 4 patients who died 7 to 42 (mean 19) days after 
severe TBI (Supplemental Table). Causes of death were multi-organ failure (n=2), elevated 
intracranial pressure (n=1), and brain death (n=1). We obtained 4 additional brains from control 
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subjects with no clinical evidence of TBI or other neurological disorders. Those subjects died 
from ruptured aortic aneurysm (n=1), liver failure (n=1), drowning (n=1), and myocardial 
infarction (n=1). First-degree relatives gave written informed consent for autopsy and tissue 
research. This study was approved by the human subjects committees of Kantonale 
Ethikkommission Zurich and Beth Israel Deaconess Medical Center. 
 
Tissue Processing. We fixed whole hypothalami in 10% buffered formalin and stored them at 
4° C. After the tissue equilibrated for 2 to 3 days in phosphate-buffered saline (PBS) with 20% 
sucrose, 10% formalin, and 0.1% diethyl pyrocarbonate (DEPC) (pH 7.4), we coronally 
sectioned the right and left halves of the hypothalamus at 40 µm in a 1:24 series. We stored 
sections at –20 °C in a cryoprotectant solution.9
 
Immunohistochemistry. We immunostained sections for hypocretin-1 (orexin A) as described 
previously.9 Briefly, after treatment with 3% hydrogen peroxide and blocking in 3% normal 
horse serum, we incubated sections overnight in goat anti-hypocretin-1 antiserum (1:5,000; 
Santa Cruz Biotechnology) and then in biotinylated donkey anti-goat secondary antiserum at 
1:500. We then exposed the sections to avidin-biotin complex and diaminobenzidine to 
produce light brown labelling of hypocretin-containing neurons. The specificity of the antiserum 
was tested and confirmed in hypothalamic tissue from hypocretin-knockout mice.12
To test whether other neurons in the lateral hypothalamus are lost with TBI, we 
immunostained adjacent sections for melanin concentrating hormone (MCH; rabbit primary 
antiserum, 1:10,000; a kind gift from Elefteria Maratos-Flier). 
Finally, to test whether gliosis accompanies hypocretin neuron loss, we double-
labelled sections for hypocretin-1 (1:5000) and glial fibrillary acidic protein (GFAP), a marker of 
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astrocytes. Hypocretin was labelled using goat anti-hypocretin-1 antiserum (1:5,000), 
biotinylated donkey-anti goat IgG (Jackson Laboratories), and Alexa 488-conjugated 
streptavidin (Invitrogen). GFAP was labelled using rabbit anti-GFAP primary antiserum 
(1:2000; Millipore) and Cy3-conjugated donkey-anti rabbit IgG secondary antiserum (Jackson 
ImmunoResearch Laboratories). 
Cell counts. After immunostaining, we examined sections at 200x with a Zeiss 
Axiophot microscope. We digitally superimposed a counting grid on every section and counted 
all hypocretin- and MCH-immunoreactive neurons across a 1:24 series of the entire 
hypothalamus. To prevent miscounting, we used a fine-scale counting grid that encompassed 
no more than 10 neurons per grid sector. Only clearly-immunolabeled neurons with neuronal 
morphology, outgoing axons and dendrites, and a nuclear void were counted. Corrections for 
cell size were not performed as our goal was to estimate cell loss relative to controls. To 
improve accuracy of cell counts, we have performed Abercrombie corrections on all neuronal 
counts.13 For each subject, total cell count estimates were performed by a conversion program, 
based upon multiplication of the cell count per section by sample frequency over the whole 
length of the hypothalamic field that contained positive cell bodies. We also counted GFAP-
immunolabeled astrocytes in 30 randomly selected 400 by 400 µm sites within the lateral and 
posterior hypothalamus. Cell counts were compared between groups using Student’s t-tests. 
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Results 
In this pilot study, the TBI patients were younger (51 ± 19 years) than the controls 
(69 ± 18 years), and all subjects were male except for one woman in the control group. 
Postmortem delays were similar in both groups (TBI: 12±3 hours, controls: 13±3 hours) 
(Supplemental Table).  
The number of hypocretin neurons in TBI subjects was 27% less than in controls 
(23,655±5,035) neurons vs. 32,318±3,060 neurons, p = 0.001) (Figure 1). Among the TBI 
patients, the number of hypocretin neurons differed moderately between the left and right sides 
of the hypothalamus and between individuals, reflecting the asymmetry and heterogeneity of 
TBI. Many hypocretin neurons in TBI patients were small and pyknotic, and the density of 
hypocretin fibers appeared reduced. Though TBI brains contained fewer hypocretin neurons, 
the neurons were distributed in a normal pattern, thus demonstrating the reliability and 
completeness of the cell counts (Figure 2). In all subjects, the complete hypocretin neuron 
field was examined (Supplemental Figure A). In controls, the total number of hypocretin 
neurons and their distribution across the lateral and posterior hypothalamus were similar to 
prior reports.7,8,14,15 
Hypothalami from TBI patients also contained intense perivascular hypocretin 
immunoreactivity (Figure 3). This amorphous staining was present around small vessels in the 
posterior and lateral hypothalamus but not elsewhere. The perivascular staining may represent 
phagocytized hypocretin peptide following damage to the hypocretin neurons (Figure 3). 
TBI patients also had fewer MCH neurons than controls (39,540±10,900 vs. 
57,176±24,016), but this reduction was not quite statistically significant (p = 0.06), probably 
because of variable numbers of MCH neurons. After exclusion of the female control subject  
because of abnormal hypocretin and MCH cell distribution (control subject 2 in Figure 1 and 
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Supplemental Table), mean age in the control group was 63±16 years. Thereafter, the 
reduction of hypocretin cells in TBI subjects compared to controls (33,342±2,785) was 29% 
(p=0.002), and the reduction of MCH cells (controls: 66,434±18,730) was 40% (p=0.003). 
The density of astrocytes as assessed by GFAP staining was significantly higher 
(21±12 vs. 7±2 per mm2, p<0.001) in TBI patients than in controls (Supplemental Figure B). 
The pattern of gliosis differed across the TBI patients. Double immunofluorescence staining 
showed that patients with more severe loss of hypocretin neurons had more GFAP-labeled 
astrocytes (r=-0.46, p=0.01).  
 
 
Discussion 
In this pilot study, we found that patients with severe TBI have a significant loss of 
hypocretin-producing neurons. This injury was not limited to the hypocretin neurons as there 
was a partial loss of neurons producing MCH and patchy gliosis throughout the hypothalamus. 
These findings demonstrate that TBI can injure the hypothalamus and suggest that reduced 
hypocretin signaling may contribute to the persistent sleepiness often seen in TBI patients. 
Furthermore, we observed a significant posttraumatic reduction of hypothalamic MCH neurons. 
Descriptions of injury in TBI often focus on the midbrain and subthalamus,16 but 
hypothalamic injury is common. One early study showed damage to the hypothalamus in 42% 
of deceased TBI patients.11 Other reports describe pituitary and hypothalamic dysfunction,17,18 
though to our knowledge, ours is the first to describe injury to specific types of hypothalamic 
neurons. In our patients, the loss of hypocretin neurons, coupled with gliosis and intense 
perivascular hypocretin-immunoreactive debris, strongly suggests that severe TBI can directly 
or indirectly kill hypocretin neurons.  Perhaps, the hypocretin neurons are injured by the same 
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shearing forces that often damage the midbrain, but vasospasm, or elevated intracranial 
pressure leading to compression or reduced perfusion of the hypothalamus may also 
contribute.11,17,18  
Chronic excessive daytime sleepiness is a major disabling symptom for many TBI 
patients, but so far, its etiology is not well understood.2 We believe that the partial loss of 
hypocretin neurons may contribute to chronic sleepiness after TBI.  Clearly, extensive loss of 
hypocretin neurons is sufficient to cause the sleepiness of narcolepsy with cataplexy,5-9  and 
some speculate that a partial loss of these cells causes the generally milder sleepiness of 
narcolepsy without cataplexy and Parkinson’s disease.14,15,19 This assumption is supported by 
our recent finding of reduced CSF hypocretin-1 levels in sleepy TBI patients who survived their 
injury.2 Although the association between lumbar CSF hypocretin levels and the number of 
intact hypocretin neurons is still poorly understood, we hypothesize that reduced CSF levels of 
hypocretin in TBI patients may reflect partial loss of the hypocretin neurons and perhaps some 
reduction in the activity of the surviving cells. Still, it is likely that reduced hypocretin signalling 
is not the only factor to cause sleepiness after TBI. About one-third of TBI patients have 
brainstem injuries, often near the midbrain tegmentum, that may disrupt ascending 
monoaminergic or cholinergic wake-promoting pathways.20 In addition, some TBI patients have 
hypersomnolence, with excessively large amounts of sleep each day. Hypersomnolence is 
common with hypothalamic and rostral brainstem injuries, but is uncommon with selective loss 
of the hypocretin neurons.21 Loss of the MCH neurons may also contribute to the 
pathophysiology of posttraumatic sleep-wake disturbances as these cells are hypothesized to 
regulate REM sleep.22,23 Overall, it seems likely that the persistent sleepiness in some TBI 
patients is due to a combination of reduced hypocretin signaling and injury to other sleep-wake 
regulating systems.  
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This study has some limitations that should be addressed in future research. We 
examined a small number of brains, and the control subjects were not fully matched. However, 
our TBI patients had significantly fewer hypocretin neurons even though they were younger 
than the controls. In addition, we did not examine other wake-promoting systems, and the 
extent of injury to other arousal pathways should be further investigated in larger human and 
animal studies. Last, we studied patients with fatal TBI, which probably introduced some 
selection bias. It is possible that non-fatal TBI is associated with a less severe loss of 
hypocretin neurons. 
TBI often results in chronic sleepiness, and the observation that wake-promoting 
hypocretin neurons are lost with TBI provides new insights into the underlying pathophysiology 
that may lead to novel treatment options. For example, stimulants such as modafinil that are 
helpful in narcolepsy and other hypocretin-deficient disorders should be studied systematically 
in affected TBI patients.24 Even better, hypocretin agonists could become an elegant and 
tailored treatment option not only for sleepy individuals with narcolepsy but also for those with 
TBI.  
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Figure 1.  
Overview of hypocretin and MCH cell counts. Patients with traumatic brain injury (TBI) have 
fewer hypocretin neurons. On average, TBI patients have a total of 23,655 hypocretin neurons, 
whereas controls have 32,318 neurons (p = 0.001). The numbers of hypocretin neurons on the 
left and right sides of the hypothalamus differ more in TBI patients, probably reflecting 
asymmetry of the trauma. TBI patients also have fewer MCH neurons than controls (39,540 in 
total vs. 57,176, p = 0.06). 
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Figure 2. 
TBI patients and controls have similar caudal-rostral distributions of hypocretin neurons. The 
graphs show the average number of hypocretin neurons per section (mean values across all 
cases). Overall, TBI patients have fewer neurons, especially in the center of the hypocretin 
field. Level a: fornix touches dorsal edge of mammillary bodies; level b: fornix next to 
paraventricular nucleus.  
 12
Hypocretin neuron loss with traumatic brain injury 
Figure 3. 
TBI patients have dense perivascular hypocretin immunoreactivity within the hypothalamic 
hypocretin field (A, B), but not in adjacent areas (C).  
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Supplemental Figure A. 
Caudal-rostral distributions  
of hypocretin neurons in  
all TBI patients and  
controls. Each graph  
displays the total number  
of hypocretin neurons  
(y axis) per section 
(x axis). Caudal sections 
are displayed on the  
left side, rostral sections  
on the right side.
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Supplemental Figure B. 
Photomicrographs depicting the relationship between gliosis (GFAP staining of astrocytes) and 
hypocretin neurons. (A) Diaminobenzidine staining of a typical astrocyte in a control brain. 
Astrocyte density is much higher in the lateral hypothalamus of a TBI brain (B1) than in the 
same region of a control patient (C1). Double immunofluorescence staining shows that along 
with the reduction in the number of hypocretin neurons (green), there is an increase in red 
GFAP-labelled astrocytes (arrow) and fibers in TBI (B2) compared to control subjects (C2). Bar: 
30 µm.  
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Supplemental Table.  
Clinical characteristics and cell counts of traumatic brain injury (TBI) patients and 
controls (Co). Severity of TBI was assessed clinically using the Glasgow Coma Scale (GCS) 
and by CT using the Marshall criteria.2 All patients were comatose from the time of injury, but 
no patient suffered a cardiac or respiratory arrest at the time of injury. None had facial or 
basilar skull fractures. TBI patient 2 had a minor subarachnoid hemorrhage. 
TBI  Age 
 
Sex Survival  
after TBI  
(days) 
Post- 
mortem  
delay  
(hours) 
GCS CT  
(Mar- 
shall) 
Cause  
of death 
 
Total  
hypocretin 
cells 
Total 
MCH 
cells 
1 57 m 14 14 7 II Multi-organ 
failure 
L: 11,485 
R: 10,402 
L: 14,085 
R: 12,078 
2 26 m 7 12 3 IV Elevated intra-
cranial pressure 
L: 13,422 
R: 10,397 
L: 23,131 
R: 17,081 
3 71 m 42 7 8 II Multi-organ 
failure 
L: 9,653 
R: 8,818 
L: 20,018 
R: 18,933 
4 49 m 12 13 3 III Brain death L: 13,126 
R: 17,315 
L: 27,142 
R: 25,693 
 
Co  Age 
 
Sex Survival  
after TBI  
(days) 
Post- 
mortem  
delay  
(hours) 
GCS CT  
(Mar- 
shall) 
Cause  
of death 
 
Total  
hypocretin 
cells 
Total 
MCH 
cells 
1 48 m n.a. 15 n.a. n.a. Ruptured aortic 
aneurysm 
L: 17,751 
R: 17,228 
L: 43,724 
R: 43,252 
2 88 f n.a. 9 n.a. n.a. Liver failure L: 14,469 
R: 14,777 
L: 15,617 
R: 13,782 
3 63 m n.a. 11 n.a. n.a. Drowning L: 17,726 
R: 17,194 
L: 29,983 
R: 32,040 
4 79 m n.a. 15 n.a. n.a. Myocardial 
infarction 
L: 15,325 
R: 14,801 
L: 25,955 
R: 24,349 
 
GCS: 3-8 = severe, 9-12 = moderate, 13-15 = mild 
CT Marshall criteria: I = no visible intracranial pathology, II-IV = midline shift, and V = mass 
lesion. 
n.a.: not applicable 
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